Czech
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

head and neck neoplasms/tyrosine

Odkaz je uložen do schránky
Strana 1 z 320 Výsledek

Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND This study was to explore whether the efficacy of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Z, Iressa, gefitinib) plus chemotherapeutic agents docetaxel (D) and cisplatin (P) may benefit from sequencing of the combination. METHODS Three head and neck

Clinical relevance of protein-tyrosine (de-)phosphorylation in head and neck cancer.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Previous studies have shown that protein tyrosine (de)phosphorylation plays an important role in head and neck cancer. Protein-tyrosine kinases (PTK) and protein-tyrosine phosphatases (PTPase) activities in the cytosol of tumor tissue were significantly increased compared to normal tissue of cancer
Head and neck cancer is a capricious disease that varies greatly in its clinical behavior. The development of biomarkers that can distinguish between biologically aggressive and indolent tumors has been a long term goal of our laboratories. Predictive markers applicable to biopsy specimens should
Overexpression of epidermal growth factor receptor (EGFR) is frequently observed in many solid tumor types, including head and neck squamous cell carcinomas (HNSCC). Recent laboratory experiments have demonstrated that high EGFR levels correlate with increased tumor resistance to radiation. This
OBJECTIVE Vandetanib (ZD6474, Zactima) is a novel, orally available inhibitor of vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase activity with additional activity against epidermal growth factor receptor (EGFR) tyrosine kinase. Vandetanib has demonstrated enhanced efficacy in

AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Purpose: Radiation and cetuximab are therapeutics used in management of head and neck squamous cell carcinoma (HNSCC). Despite clinical success with these modalities, development of both intrinsic and acquired resistance is an emerging problem in the management of

Melanoma-associated antigen expression and the efficacy of tyrosine kinase inhibitors in head and neck cancer.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Melanoma-associated antigen (MAGE) has been identified in a variety of types of cancer. The expression of several MAGE subgroups is correlated with poor prognosis and chemotherapeutic resistance. One target of chemotherapeutic treatment in head and neck cancer is the epidermal growth factor receptor

Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
One of the mechanisms of the antitumor activity of green tea (-)-epigallocatechin-3-gallate (EGCG) is associated with its effect on epidermal growth factor receptor (EGFR)-mediated signaling transduction pathways. We investigated whether combining EGCG with the EGFR-tyrosine kinase inhibitor

Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Head and neck squamous cell carcinoma (HNSCC) remains a clinical challenge and identification of novel therapeutic targets is necessary. The receptor tyrosine kinase AXL has been implicated in several tumor entities and a selective AXL small molecule inhibitor (BGB324) is currently being tested in

Emerging tyrosine kinase inhibitors for head and neck cancer.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
BACKGROUND Conventional treatments for head and neck squamous cell cancer (HNSCC) are not completely effective and present several issues in terms of toxicity. Treatments available consist of surgery, chemoradiotherapy and biological agents. METHODS Tyrosine-kinase inhibitors (TKIs) alone or in

Aberrant tyrosine phosphorylation in head and neck tumours and potentially premalignant tissues.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Protein tyrosine kinases (PTK) and protein tyrosine phosphatases (PTPase) activity in tumor tissue, obtained from 107 patients with squamous cell carcinoma of the upper aerodigestive tract, was determined. In 79 patients samples were also taken from a histologically proven non-tumourous part of the

Identification of tyrosine kinases overexpressed in head and neck cancer.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
OBJECTIVE To identify protein-tyrosine kinases (PTKs) that may be involved in the development and progression of head and neck squamous cell carcinoma (HNSCC). METHODS Messenger RNA from 7 HNSCC specimens was reverse transcribed to complementary DNA, and selective amplification of PTK complementary
BACKGROUND Addition of erlotinib to metronomic chemotherapy (MCT) may lead to further improvement in progression-free survival (PFS) and overall survival in head and neck cancers. The aim of this study was to study the PFS with MCT + erlotinib combination in our setting. METHODS A single-arm

Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Spleen tyrosine kinase (SYK) is a promoter of cell survival in a variety of cell types, including normal and cancerous epithelial cells. We hypothesized that SYK would an important therapeutic target to inhibit for the treatment of HNSCC.SYK protein

Apoptosis and growth inhibition of head and neck tumor cell line induced by epidermal growth factor receptor tyrosine kinase inhibitor.

Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Overexpression of the epidermal growth factor (EGF) receptor, a hallmark of aerodigestive squamous cell carcinoma of the head and neck (SCCHN), correlates with aggressive tumor behavior. There is evidence that SCCHN cells auto-activate their EGF receptors. The receptor has therefore attracted
Připojte se k naší
facebookové stránce

Nejúplnější databáze léčivých bylin podložená vědou

  • Funguje v 55 jazycích
  • Bylinné léky podporované vědou
  • Rozpoznávání bylin podle obrázku
  • Interaktivní mapa GPS - označte byliny na místě (již brzy)
  • Přečtěte si vědecké publikace související s vaším hledáním
  • Hledejte léčivé byliny podle jejich účinků
  • Uspořádejte své zájmy a držte krok s novinkami, klinickými testy a patenty

Zadejte symptom nebo chorobu a přečtěte si o bylinách, které by vám mohly pomoci, napište bylinu a podívejte se na nemoci a příznaky, proti kterým se používá.
* Všechny informace vycházejí z publikovaného vědeckého výzkumu

Google Play badgeApp Store badge